ABM Therapeutics, Inc.
璧辰医药
ABM Therapeutics, Inc.
Biotech/Healthcare
ABM Therapeutics develops small-molecule targeted oncology drugs. Its proprietary next-generation BRAF inhibitor, ABM-1310, is designed to treat multiple malignant tumors and brain metastases.
Latest round: Series B (2022)
Source: ChinaBulls — chinabulls.com
Last updated 2022-01-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.